Avicanna Inc., a biopharmaceutical company focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based products is pleased to announce Aras Azadian CEO of Avicanna will be delivering a presentation live at the Life Science Investor Forum with Virtual Investor Conference hosted by VirtualInvestorConferences.com on June 20, 2024.
Aras Azadian will provide a corporate update on Avicanna and will then also be joined by Brad Sorensen, senior equity research analyst with Zacks Small-Cap research for a fire-side chat. This will be a live, interactive online event where attendees have the opportunity to ask the Company questions in real-time. If attendees are not able to join the event live on the day of the conference, an archived webcast will also be made available after the event.
DATE: June 20th 2024
TIME: 12:00pm EST
LINK: https://bit.ly/3yznnKX
It is recommended that online investors pre-register and run the online system check to expedite participation and receive event updates. Learn more about the event at www.virtualinvestorconferences.com.
Recent Company Highlights
- First adjusted EBITDA positive quarter in Avicanna’s history
- 2023-year end results and Avicanna achieving 314% year-over-year revenue increase
- First indication-specific drug approval of Avicanna’s Trunerox® product
About Avicanna Inc.
Avicanna is a commercial-stage international biopharmaceutical company focused on the advancement and commercialization of cannabinoid-based products and formulations for the global medical and pharmaceutical market segments. Avicanna has an established scientific platform including R&D and clinical development leading to the commercialization of more than thirty proprietary, evidence-based finished products and supporting four commercial stage business pillars.
